[en] The selectivity of [F-18]MPPF (fluorine-18-labeled 4-(2'-methoxyphenyl)-1-[2'-(N-2"-pirydynyl)-p-fluorobenzamido]ethylpiperazine) for serotonergic 5-hydroxytryptamine(1A) (5-HT1A) receptors has been established in animals and humans. The authors quantified the parameters of ligand-receptor exchanges using a double-injection protocol. After injection of a tracer and a coinjection dose of [F-18]MPPF, dynamic positron emission tomography (PET) data Were acquired during a 160-minute session in five healthy males. These PET and magnetic resonance imaging data were coregistered for anatomical identification. A three-compartment model was used to determine six parameters: F-v (vascular fraction). K-1, k(2) (plasma/free compartment exchange rate). k(off). k(on)/V-r (association and dissociation rate), B-max (receptor concentration), and to deduce K-d (apparent equilibrium dissociation rate). The model was fitted with regional PET kinetics and arterial input function corrected for metabolites. Analytical distribution volume and binding potential Were compared With indices generated by Logan-Patlak graphical analysis. The 5HT(1A) specificity for MPPF was evidenced. A B-max of 2.9 pmol/mL and a K-d of 2.8 nmol/L were found in hippocampal regions, K-d and distribution volume in the free compartment were regionally stable. and the Logan binding potential was linearly correlated to B-max. This study confirms the value of MPPF in the investigation of normal and pathologic systems involving the limbic network and 5-HT1A receptors. Standard values can be used for the simulation of simplified protocols.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Costes, Nicolas
Merlet, I.
Zimmer, L.
Lavenne, F.
Cinotti, L.
Delforge, Jacques
Luxen, André ; Université de Liège - ULiège > Chimie organique de synthèse
Pujol, Jean-François
Le Bars, D.
Language :
English
Title :
Modeling [F-18]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection
Brix G., Zaers J., Adam L.E., Bellemann M.E., Ostertag H., Trojan H., Haberkorn U., Doll J., Oberdorfer F., Lorenz W.J. (1997) Performance evaluation of a whole-body PET scanner using the NEMA protocol. J Nucl Med , National Electrical Manufacturers Association; 38:1614-1623.
Burnet P.W., Eastwood S.L., Harrison P.J. (1997) [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: A comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30:565-574.
Chugani D.C., Muzik O., Chakraborty P., Mangner T., Chugani H.T. (1998) Human brain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl-L-tryptophan. Synapse 28:33-43.
Cliffe I.A. (2000) A retrospect on the discovery of WAY-100635 and the prospect for improved 5-HT(1A) receptor PET radioligands. Nucl Med Biol 27:441-447.
Cowen P.J. (2000) Psychopharmacology of 5-HT(1A) receptors. Nucl Med Biol 27:437-439.
Delforge J., Syrota A., Mazoyer B.M. (1989) Experimental design optimisation: Theory and application to estimation of receptor model parameters using dynamic positron emission tomography. Phys Med Biol 34:419-435.
Delforge J., Syrota A., Mazoyer B.M. (1990) Identifiability analysis and parameter identification of an in vivo ligand-receptor model from PET data. IEEE Trans Biomed Eng 37:653-661.
Delforge J., Pappata S., Millet P., Samson Y., Bendriem B., Jobert A., Crouzel C., Syrota A. (1995) Quantification of benzodiazepine receptors in human brain using PET, [11C]flumazenil, and a single-experiment protocol. J Cereb Blood Flow Metab 15:284-300.
Delforge J., Syrota A., Bendriem B. (1996) Concept of reaction volume in the in vivo ligand-receptor model. J Nucl Med 37:118-125.
Farde L., Ito H., Swahn C.G., Pike V.W., Halldin C. (1998) Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J Nucl Med 39:1965-1971.
Ginovart N., Hassoun W., Le Bars D., Weissmann D., Leviel V. (2000) In vivo characterization of p-[(18)F]MPPF, a fluoro analog of WAY-100635 for visualization of 5-HT(1a) receptors. Synapse 35:192-200.
Gunn R.N., Sargent P.A., Bench C.J., Rabiner E.A., Osman S., Pike V.W., Hume S.P., Grasby P.M., Lammertsma A.A. (1998) Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 8:426-440.
Hall H., Lundkvist C., Halldin C., Farde L., Pike V.W., McCarron J.A., Fletcher A., Cliffe I.A., Barf T., Wikstrom H., Sedvall G. (1997) Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635. Brain Res 745:96-108.
Hume S., Hirani E., Opacka-Juffry J., Myers R., Townsend C., Pike V., Grasby P. (2001) Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(1A) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine. Synapse 41:150-159.
Koeppe R.A., Holthoff V.A., Frey K.A., Kilbourn M.R., Kuhl D.E. (1991) Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735-744.
Le Bars D., Lemaire C., Ginovart N., Plenevaux A., Aerts J., Brihaye C., Hassoun W., Leviel V., Mekhsian P., Weissmann D., Pujol J.F., Luxen A., Comar D. (1998) High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. Nucl Med Biol 25:343-350.
Le Bars D., Bonmarchand G., Alvarez G., Lemaire C., Mosdzianowski C. (2001) New automation of MPPF using a coincidence synthesizer: 14th International Symposium on Radiopharmaceuticals. J Labeled Cpd Radiopharm 44.
Logan J., Fowler I.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J. (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740-747.
Louw D., Sutherland G.R., Glavin G.B., Girvin J. (1989) A study of monoamine metabolism in human epilepsy. Can J Neurol Sci 16:394-397.
Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-227.
Passchier J., Van Waarde A., Pieterman R.M., Elsinga P.H., Pruim J., Hendrikse H.N., Willemsen A.T., Vaalburg W. (2000) In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF. J Nucl Med 41:1830-1835.
Passchier J., Van Waarde A., Pieterman R.M., Elsinga P.H., Pruim J., Hendrikse H.N., Willemsen A.T., Vaalburg W. (2000) Quantitative imaging of 5-HT(1A) receptor binding in healthy volunteers with [(18)f]p-MPPF. Nucl Med Biol 27:473-476.
Passchier J., Van Waarde A., Vaalburg W., Willemsen A.T. (2001) On the quantification of [18F]MPPF binding to 5-HT1A receptors in the human brain. J Nucl Med 42:1025-1031.
Pike V.W., McCarron J.A., Lammerstma A.A., Hume S.P., Poole K., Grasby P.M., Malizia A., Cliffe I.A., Fletcher A., Bench C.J. (1995) First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. Eur J Pharmacol 283.
Pike V.W., McCarron J.A., Lammertsma A.A., Osman S., Hume S.P., Sargent P.A., Bench C.J., Cliffe I.A., Fletcher A., Grasby P.M. (1996) Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. Eur J Pharmacol 301.
Pintor M., Mefford I.N., Hutter I., Pocotte S.L., Wyler A.R., Nadi N.S. (1990) Levels of biogenic amines, their metabolites, and tyrosine hydroxylase activity in the human epileptic temporal cortex. Synapse 5:152-156.
Plenevaux A., Lemaire C., Aerts J., Lacan G., Rubins D., Melega W.P., Brihaye C., Degueldre C., Fuchs S., Salmon E., Maquet P., Laureys S., Damhaut P., Weissmann D., Le Bars D., Pujol J., Luxen A. (2000) [(18)F]p-MPPF: A radiolabeled antagonist for the study of 5-HT(1A) receptors with PET. Nucl Med Biol 27:467-471.
Plenevaux A., Weissmann D., Aerts J., Lemaire C., Brihaye C., Degueldre C., Le Bars D., Comar D., Pujol J., Luxen A. (2000) Tissue distribution, autoradiography, and metabolism of 4-(2′methoxyphenyl)-1-[2′-[N-2′-pyridinyl)-p-[(18)F] fluorobenzamido]ethyl]piperazine (p-[(18)F]MPPF), a new serotonin 5-HT(1A) antagonist for positron emission tomography: An in vivo study in rats. J Neurochem 75:803-811.
Statnick M.A., Dailey J.W., Jobe P.C., Browning R.A. (1996) Abnormalities in 5-HT1A and 5-HT1B receptor binding in severe-seizure genetically epilepsy-prone rats (GEPR-9s). Neuropharmacology 35:111-118.
Wada Y., Shiraishi J., Nakamura M., Koshino Y. (1997) Role of serotonin receptor subtypes in the development of amygdaloid kindling in rats. Brain Res 747:338-342.
Woods R.P., Cherry S.R., Mazziotta J.C. (1992) Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16:620-633.
Zhuang Z.P., Kung M.P., Chumpradit S., Mu M., Kung H.F. (1994) Derivatives of 4-(2′-methoxyphenyl)-1-[2′-(N-2″ -pyridinyl-piodobenzamido)ethyl]pipera zine (p-MPPI) as 5-HT1A ligands. J Med Chem 37:4572-4575.
